Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PTH test could Fine-Tune mineral balance in kidney dialysis

NCT ID NCT02859220

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new method of measuring parathyroid hormone (PTH) can help doctors better manage calcium and phosphate levels in people on hemodialysis. About 80 patients with end-stage kidney disease will be randomly assigned to have their PTH measured either with the standard test or with a newer test that distinguishes between active and inactive PTH fragments. The goal is to see if the new test helps patients more easily meet international targets for calcium, phosphorus, and related minerals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PTH 1-84 Complete (CAP) and ratio PTH 1-84/7-84 measurement
What this could lead to
If successful, this could improve how doctors adjust treatment for calcium and phosphate imbalances in dialysis patients, helping them meet health targets more easily.
What could go wrong
This is a small, early-stage study focused on testing a measurement method, not a treatment. The new test may not lead to better patient outcomes or may be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

85 people

The number who actually took part.

Start date

Jan 2006

Finished

Jan 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * replacement therapy by hemodialysis for at least three months in the hemodialysis center of Nantes University Hospital, * intact PTH ≥ 100 pg / mL during the visit of inclusion. Exclusion Criteria: * intact PTH \<100 pg / mL during the visit of inclusion * Life expectancy estimated at less than one year at the time of inclusion, because of a disease diagnosed prior to the initiation of the study, * bone pathology diagnosed prior to the initiation of the study that interfere with calcium and phosphate metabolism (myeloma, Paget ...).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodialysis patients

Contacts and locations

Locations

  • CHU de Nantes

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.